SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form 8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
November
7, 2008
Date
of Report
(Date
of earliest event reported)
PRO-PHARMACEUTICALS,
INC.
(Exact
name of Registrant as specified in its charter)
|
Nevada |
000-32877 |
04-3562325 |
|
(State
or other jurisdiction of |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
7 Wells Avenue Newton, Massachusetts 02459 |
|
(Address of principal executive offices) (Zip code) |
(617) 559-0033
(Registrant’s telephone number, including
area code)
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
2.02. Results of Operations and Financial Condition.
On November 7, 2008, Pro-Pharmaceuticals, Inc. (the “Company”) issued a news release announcing its financial results for the three and nine months ended September 30, 2008. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report (including the exhibit) is furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.
Item
9.01. Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Shell Company Transactions
Not applicable.
(d) Exhibits.
| Exhibit Number | |||
| 99.1 | News release of Pro-Pharmaceuticals, Inc., dated November 7, 2008, entitled “Pro-Pharmaceuticals Reports Third Quarter Results”. | ||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PRO-PHARMACEUTICALS, INC. |
|||
|
|
|||
|
|
|
By: |
/s/ Anthony D. Squeglia |
|
Anthony D. Squeglia |
|||
|
Chief Financial Officer |
|||
|
Date: |
November 7, 2008 |
||
EXHIBIT INDEX
|
Exhibit |
Description |
|
| 99.1 |
News release dated November 7, 2008 entitled “Pro-Pharmaceuticals Reports Third Quarter Results”. |